Amicus Therapeutics (FOLD) Q4 2025 earnings summary

Executive summary

• Full-year 2025 total revenue reached $634M, up 17% year-over-year at constant exchange rates (CER), with a $14M currency tailwind.

• Cash position increased by $44M to $294M at year-end 2025.

• Definitive agreement for acquisition by BioMarin at $14.50 per share, valuing equity at ~$4.8B, expected to close in Q2 2026.

Financial highlights

• Galafold net product sales for 2025 were $521.7M, up 14% year-over-year (12% at CER).

• Pombiliti + Opfolda net product sales for 2025 were $112.5M, up 60% year-over-year (56% at CER).

• GAAP net loss for 2025 was $27.1M ($0.09 per share), improved from $56.1M loss in 2024.

• Non-GAAP net income for 2025 was $96.8M ($0.31 per share), up from $73.9M in 2024.

• Total GAAP operating expenses rose 17% to $528.5M; non-GAAP operating expenses rose 24% to $431.9M.

Outlook and guidance

• No financial guidance for 2026 provided due to pending acquisition by BioMarin.